{"abstract":"The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to RNAceuticals, Inc. located at 12 Indian Trail Road, Woodbridge, CT, USA to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/07/10/2020-14836.html","cfr_references":[],"citation":"85 FR 41607","comment_url":null,"comments_close_on":"2020-07-27","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, on or before July 27, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-14836","effective_on":null,"end_page":41608,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/07/10/2020-14836.xml","html_url":"https://www.federalregister.gov/documents/2020/07/10/2020-14836/prospective-grant-of-exclusive-patent-commercialization-license-n6-a-novel-broad-highly-potent","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-14836?publication_date=2020-07-10","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-07-10/2020-14836/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":553,"last_updated":"2026-08-25 00:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-07-10/pdf/2020-14836.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-14836.pdf?1594298742","publication_date":"2020-07-10","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/07/10/2020-14836.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:53:48Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":41607,"subtype":null,"title":"Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV-1 Strains","toc_doc":"N6, A Novel, Broad, Highly Potent HIV-Specific Antibody and A Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV1 Strains","toc_subject":"Prospective Grant of Exclusive Patent Commercialization License:\n","topics":[],"type":"Notice","volume":85}